PHRI research on diabetes is well represented at the 55th annual meeting of the European Association for the Study of Diabetes (EASD 2019) in Barcelona, Spain Sept. 16 – 20, 2019.
- Unique features and findings of the long-term REWIND (researching cardiovascular events with a weekly incretin in diabetes) trial, presented by Hertzel Gerstein. Sept. 19, 12:00 Barcelona time, Vilanova Hall.
- REMIT-DAPA trial (diabetes regression and remission following a short-term intensive metabolic intervention with insulin glargine, metformin and dapagliflozin) poster presentation by Natalia McInnes. Sept. 19, 13:15.
- Angiotensin-converting enzyme and type 2 diabetes risk: a Mendelian randomization study: oral presentation by Marie Pigeyre, Sept. 19, 15:00, Serrano-Rios Hall.
- Novel biomarkers predicting renal decline in people with dysglycemia in the ORIGIN trial: oral presentation by Hertzel Gerstein, Sept. 19, 15:30, Vilanova Hall.
Next month, PHRI will share research at the 2019 Diabetes Canada/Canadian Society of Endocrinology and Metabolism professional conference, in Winnipeg, Canada.
.@PHRIresearch‘s Hertzel Gerstein and Natalia McInnes will present at #DCAN19 Oct. 4, 16:00 CT on REMIT-DAPA study: #diabetes remission & regression following short-term intensive metabolic intervention w/ insulin glargine, metformin and #dapagliglozin. @DiabetesCanada @CSEM_SCEM https://t.co/4O2t4rq3cw
— PHRI Population Health Research Institute 🇨🇦 (@PHRIresearch) September 17, 2019